Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00110942
Status:
COMPLETED
Last Update Posted:
2008-06-23
First Post:
2005-05-16
Brief Title:
Treatment for Patients With Osteoarthritis OA
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Multiple Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of Systemic AMG 108 in Subjects With Osteoarthritis OA
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the clinical benefit change in Western Ontario and McMaster University Osteoarthritis Index WOMAC pain score of AMG 108 300 mg subcutaneously SC every 4 weeks in subjects with OA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None